CurrentCapital BluecrossPolicy MP 2.092

Percutaneous electrical nerve field stimulation, cranial electrotherapy stimulation, auricular electrostimulation, and external trigeminal nerve stimulation

Coverage criteria and medical policy for several noninvasive electrical stimulation therapies (IB‑Stim PENFS, cranial electrotherapy stimulation, auricular electrostimulation, and external trigeminal nerve stimulation) as applied to Capital Blue Cross products.

Policy Summary

PayerCapital Bluecross

PolicyPercutaneous electrical nerve field stimulation, cranial electrotherapy stimulation, auricular electrostimulation, and external trigeminal nerve stimulation

Policy CodePolicy MP 2.092

Change TypeMinor reviewMN criteria added (11/29/2023)consensus review (04/17/2024)

Effective DateSep 1, 2024

Next Review DateN/A

Key ActionConfirm prior authorization and document age (11–18 years), required diagnoses (IBS + abdominal pain), and planned device use ≤4 weeks when requesting coverage for IB‑Stim PENFS.

SourceLink

POLICY UPDATE CHANGES

11/29/2023 Minor Review. Added MN criteria for the IB-stim device. Updated background, rationale, coding table, and references.

04/17/2024 Consensus Review. Updated background, rationale, and references. No changes to coding.

12/12/2023 Administrative Update. Deleted K1002, K1016, K1017. Added E0732-E0733.

08/15/2019 Consensus Review. Policy statement unchanged. Tables under Background/Description section updated. References Updated.

11-18age range covered for IB‑Stim PENFS

≤4 wksmaximum duration allowed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

0720Tcovered procedure code

6 listedinvestigational procedure codes

04/17/2024most recent consensus review

Coverage Criteria and Policy Statements

Policy updates and coding history

08/15/2019 — Consensus review; policy statement unchanged. Background/Description tables updated; references updated.

01/01/2020 — Administrative update; added code K1002.

07/01/2020 — Consensus review; no changes. References updated and coding reviewed.

03/10/2021 — Consensus review; no changes to policy statement. References updated and coding reviewed; Background/Description updated.

05/27/2021 — Consensus review; added codes K1016 and K1017. Background/Description and references updated.

09/20/2021 — Minor review; added Percutaneous Electrical Nerve Field Stimulator to policy as Not Medically Necessary (NMN). Added CPT code 64999 and HCPCS code E1399 as NMN for treatment of functional abdominal pain.

05/11/2022 — Consensus review; updated coding and references.

06/10/2022 — Administrative update; added procedure code 0720T effective 07/01/2022.

09/12/2022 — Administrative update; added procedure code A4596 effective 10/01/2022.

11/29/2022 — Administrative update; added procedure code 0783T.

04/06/2023 — Consensus review; updated background, rationale, and references.

11/29/2023 — Minor review; added medical necessity criteria for the IB‑Stim device. Updated background, rationale, coding table, and references.

12/12/2023 — Administrative update; deleted codes K1002, K1016, K1017. Added HCPCS E0732 and E0733.

04/17/2024 — Consensus review; updated background, rationale, and references. No changes to coding.

Coding, Procedure, and Diagnosis Codes

FDA product codes and device referencesmixed

QHH	FDA product code referenced for IB‑Stim and derivatives
QJQ	FDA product code referenced for cranial electrotherapy stimulation devices
BWK	FDA product code referenced for auricular electrostimulation devices
PZR	FDA product code referenced for auricular electrostimulation devices
QGL	FDA product code referenced for eTNS (Monarch) devices

Investigational; therefore, not covered: Procedure CodesCPTNot Covered

A4596
E0732
E0733
S8930
64999
0783T

Covered when medically necessary for the treatment of functional abdominal pain: Procedure CodesCPTCovered

0720T

Diagnosis codes referenced for medical necessityICD-10

K58.0	Irritable bowel syndrome with diarrhea.
K58.1	Irritable bowel syndrome with constipation.
K58.2	Mixed irritable bowel syndrome.
K58.8	Other irritable bowel syndrome.
K58.9	Irritable bowel syndrome without diarrhea.
R10.10	Upper abdominal pain, unspecified.
R10.11	Right upper quadrant pain.
R10.12	Left upper quadrant pain.
R10.13	Epigastric pain.
R10.30	Lower abdominal pain, unspecified.

1–10 of 31

1/4

Policy-related procedure/HCPCS/CPT codes (added/removed over time)mixed

K1002	Temporary code previously added (deleted 12/12/2023)
K1016	Temporary code previously added (deleted 12/12/2023)
K1017	Temporary code previously added (deleted 12/12/2023)
E0732	Added 12/12/2023
E0733	Added 12/12/2023
0720T	Procedure code added 06/10/2022 effective 7/1/2022
A4596	Added 09/12/2022 effective 10/1/2022
0783T	Added 11/29/2022
E1399	Previously listed as NMN for treatment of functional abdominal pain
64999	Unlisted procedure code previously listed as NMN for treatment of functional abdominal pain

Study sample size — PENFS evidence

Study sample sizeN=115 (randomized controlled trial including adolescents ages 11–18)

Population detailsHeterogeneous adolescent patients with pain-related functional gastrointestinal disorders

Treatment duration in RCT3 weeks (with follow-up up to 12 weeks)

(No label)(No specific value provided in brief)

Inventory notePlaceholder included for completeness; no data extracted

Provider Requirements, Authorization, and Documentation

Prior Authorization

Preauthorization / Coverage Note

Coverage and prior authorization requirements vary by member benefit plan. The existence of this medical policy does not mean the service is a covered benefit for a given member. Benefit determinations should be based on the member's health benefit plan language and providers or members should contact Capital BlueCross to confirm coverage and any preauthorization requirements.

Benefit determinations are governed by the member's health benefit plan; this policy is not a description of benefits.
Preauthorization requirements vary by product/program and must be confirmed with Capital BlueCross.

Billing Rule

Prior Authorization and Coding Note

Providers should follow plan rules for prior authorization and coding. The presence of codes in the coding section does not guarantee coverage — confirm with the member's benefit plan. Certain procedure and HCPCS codes have been added, deleted, or updated in prior revisions; use current valid codes and obtain prior authorization when required by the member's plan.

Background and Clinical Context

Irritable bowel syndrome (IBS) is described in the policy as a gut–brain interaction disorder causing abdominal pain with diarrhea and/or constipation and is often diagnosed in younger patients. The policy places IB‑Stim PENFS within this clinical context as a nonpharmacologic, percutaneous nerve-field stimulation technique evaluated specifically for pediatric functional abdominal pain associated with IBS, with the only supported coverage limited to adolescents meeting the policy’s age, diagnosis, and duration criteria.

Device and Therapy Definitions

PENFS — definition and device example

DefinitionPercutaneous electrical nerve field stimulation (PENFS) is a nonimplantable device using a percutaneous electrode array placed behind the ear to stimulate cranial nerve peripheral branches to modulate pain signals (example: IB‑Stim).

Device exampleIB‑Stim — disposable, battery-operated device with a multiwire electrode array placed at preauricular, lobule, and superior crus sites

Mechanism/placementThin-needle electrodes attach to the ear at points where cranial nerve branches are located just beneath the skin

Cranial electrotherapy stimulation (CES)

DefinitionCranial electrotherapy stimulation (CES) delivers weak pulses of electrical current to the earlobes, mastoid processes, or scalp to modulate brain networks; it has been evaluated for anxiety, depression, insomnia, pain, and other conditions.

Revision History and Policy Changes

2024-04-17Consensus ReviewLatest

Updated background, rationale, and references; no changes to coding.

2023-12-12Administrative Update

Deleted temporary codes K1002, K1016, and K1017; added HCPCS E0732 and E0733.

2023-11-29Minor Review

Policy Summary

PayerCapital Bluecross

PolicyPercutaneous electrical nerve field stimulation, cranial electrotherapy stimulation, auricular electrostimulation, and external trigeminal nerve stimulation

Policy CodePolicy MP 2.092

Change TypeMinor reviewMN criteria added (11/29/2023)consensus review (04/17/2024)

Effective DateSep 1, 2024

Next Review DateN/A

Key ActionConfirm prior authorization and document age (11–18 years), required diagnoses (IBS + abdominal pain), and planned device use ≤4 weeks when requesting coverage for IB‑Stim PENFS.

SourceLink

On This Page

Retain as empty key-value placeholder

Administrative updates: added 0720T (effective 7/1/2022), A4596 (effective 10/1/2022), 0783T, E0732-E0733; deleted K1002, K1016, K1017 (deleted 12/12/2023).
Identification of a code here does not denote coverage; follow member benefit terms and prior authorization processes.

Denial Risk

Denial Triggers for IB‑Stim PENFS

Use of IB‑Stim PENFS outside the policy's medical necessity criteria, or when not a covered benefit per the member's plan, may result in claim denials. Services listed as investigational are not covered unless the member's plan specifically provides coverage.

Denial may occur if device use is beyond specified age range (not 11–18) or exceeds allowed duration.
Services coded with investigational procedure codes (e.g., A4596, E0732, E0733, S8930, 64999, 0783T) may be denied as not covered per plan terms.
0720T is covered only when medically necessary for functional abdominal pain per criteria; otherwise it may be denied.

Billing Rule

Coding Mismatch Risk

Claims using deleted or inappropriate codes, or unlisted codes without supporting justification, may trigger coding/audit issues and denials. Ensure submitted codes are current and supported by documentation.

Deleted codes (K1002, K1016, K1017) must not be used after 12/12/2023.
Using unlisted or legacy codes without clinical justification and appropriate documentation may result in payment denial or audit.

Documentation Required

Required Documentation for IB‑Stim PENFS

Document medical necessity for IB‑Stim PENFS thoroughly. Required documentation must support age, diagnosis, duration, and prior conservative therapy as applicable.

Patient age documented as 11–18 years.
Diagnosis documentation: one ICD-10 code from the K58 (IBS) series AND one from the R10 (abdominal pain) series as listed in the policy.
Documentation of intended duration of use (will not exceed 4 weeks per policy) and that the device is intended to be used in combination with other IBS therapies as indicated by device labeling and policy.
Evidence of prior first-line treatments (e.g., dietary changes, other nonpharmacologic or pharmacologic therapies) as clinically appropriate for IBS in children/adolescents.

Step Therapy

Step Therapy Context

Step-therapy context: First-line IBS treatments generally involve dietary changes and other nonpharmacologic therapies; PENFS (IB‑Stim) is considered when these first-line options and age-appropriate pharmacologic options have been tried or are not appropriate.

Document prior dietary or other first-line treatments and rationale for PENFS.
PENFS is often considered for children/adolescents due to limited FDA-approved pharmacologic options in this population.

Alpha-Stim® — provides pulsed, low-intensity current via clip electrodes attaching to earlobes

Typical administrationTreatments may be once or twice daily over several days to several weeks

Auricular electrostimulation

DefinitionAuricular electrostimulation stimulates auricular acupuncture points using ambulatory ear devices (e.g., P‑Stim) applied behind the ear and connected to acupuncture needles or electrode patches.

Device exampleP‑Stim — single-use miniature stimulator worn behind the ear, preprogrammed on/off cycles and connects to inserted acupuncture needles

Indications under studyEvaluated for pain, insomnia, depression, anxiety, weight loss, and opioid withdrawal

External trigeminal nerve stimulation (eTNS)

DefinitionExternal trigeminal nerve stimulation (eTNS) is a noninvasive, wearable TENS-like therapy that delivers low-level pulses to branches of the trigeminal nerve, typically via a forehead patch, to modulate brain regions involved in attention and behavior.

Device exampleMonarch eTNS — portable pulse generator with single-use forehead patch; FDA-cleared (de novo) for pediatric ADHD ages 7–12

MechanismLow-level electrical signals transmitted to forehead patch stimulate trigeminal nerve fibers influencing brain regions regulating attention/behavior

eTNS — prescription TENS device example (Monarch)

DefinitionExternal Trigeminal Nerve Stimulation (eTNS) refers to a prescription TENS device (e.g., Monarch) that delivers low-level electrical pulses via a forehead patch and is FDA-marketed/cleared for pediatric use (ages 7–12) under the de novo pathway.

Regulatory noteMonarch eTNS received FDA marketing authorization in 2019; Generation 2.0 and Smile eTNS deemed substantially equivalent in 2023 (product code QGL)

Use settingIntended for home use under caregiver supervision

Percutaneous Electrical Nerve Field Stimulation (PENFS)

DefinitionPercutaneous Electrical Nerve Field Stimulation (PENFS) is a percutaneous neurostimulation technique using a behind‑the‑ear electrode array (e.g., IB‑Stim) evaluated for adolescent abdominal pain and IBS with limited randomized controlled trial evidence.

Clinical evidenceEvidence includes a subgroup analysis from one RCT (N=115) in adolescents showing pain reduction at end of treatment compared with sham, but with limitations (small size, heterogeneous disorders, short follow-up).

Typical applicationDevice is disposable and intended for short duration use (policy limits ≤4 weeks) for functional abdominal pain associated with IBS in ages 11–18

CES / Auricular electrostimulation — overview

DefinitionCES and auricular electrostimulation are noninvasive head/ear electrostimulation techniques studied for headache, chronic pain, psychiatric and neurologic conditions, obesity, and opioid withdrawal, but evidence is insufficient to establish broad clinical benefit.

Evidence limitationsTrials are generally small, methodologically limited, and produce inconsistent results across indications

Representative devicesAlpha-Stim (CES), P‑Stim (auricular) among others with various 510(k) listings

IB‑Stim device — policy reference

Reference to IB‑Stim MN criteriaIB‑Stim device referenced with medical necessity criteria added in the 11/29/2023 minor review (policy update).

Policy action11/29/2023 Minor Review: added MN criteria for the IB‑Stim device and updated background, rationale, coding table, and references.

Documentation implicationDevice-specific MN documentation will be required when billing the IB‑Stim device per policy updates.

CES — supporting references

Definition / referenceCranial electrotherapy stimulation (CES) — cranial electrotherapy stimulation references and systematic reviews are cited in the policy literature and used as background for coverage conclusions.

Key literatureMultiple systematic reviews and randomized trials cited (e.g., Cochrane and recent meta-analyses) informing insufficient evidence conclusions for many CES indications.

Policy roleCES references support the policy's investigational stance for many applications beyond limited or marginal benefits observed in pooled analyses.

Added medical necessity criteria for the IB‑Stim device and updated background, rationale, coding table, and references.

2022-11-29Administrative Update

Added procedure code 0783T to the policy.

2022-09-12Administrative Update

Added procedure code A4596 effective 10/01/2022.

2022-06-10Administrative Update

Added procedure code 0720T effective 07/01/2022.

2021-09-20Minor Review

Added percutaneous electrical nerve field stimulator to the policy as Not Medically Necessary and listed CPT 64999 and HCPCS E1399 as NMN for treatment of functional abdominal pain.

2021-05-27Consensus Review

Added temporary codes K1016 and K1017 and updated background/description and references.

2021-03-10Consensus Review

Consensus review with no changes to the policy statement; references updated and coding reviewed.

2020-01-01Administrative Update

Added new temporary code K1002.

2019-08-15Consensus Review

Consensus review with policy statement unchanged; background/description tables and references updated.

Administrative and minor reviews recorded in the policy note multiple coding changes over time. Changes include addition of procedure code 0720T (covered when medically necessary for functional abdominal pain), addition of A4596 and 0783T, and later deletions of temporary codes K1002, K1016, K1017; providers should refer to the coding table and revision history when submitting claims.

No additional provider revision notes were recorded in this update beyond the coding and minor review actions documented in the policy history (coding additions, deletions, and the November 29, 2023 addition of medical necessity criteria for the IB‑Stim device).